John G Ullman & Associates Inc. Has $446,000 Position in Laboratory Corporation of America Holdings (LH)

John G Ullman & Associates Inc. boosted its position in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 4.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,892 shares of the medical research company’s stock after buying an additional 118 shares during the period. John G Ullman & Associates Inc.’s holdings in Laboratory Corporation of America Holdings were worth $446,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Regentatlantic Capital LLC boosted its position in Laboratory Corporation of America Holdings by 0.5% in the second quarter. Regentatlantic Capital LLC now owns 1,696 shares of the medical research company’s stock worth $261,000 after buying an additional 8 shares during the last quarter. Endurance Wealth Management Inc. boosted its position in Laboratory Corporation of America Holdings by 0.7% in the first quarter. Endurance Wealth Management Inc. now owns 1,510 shares of the medical research company’s stock worth $217,000 after buying an additional 10 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in Laboratory Corporation of America Holdings by 0.6% in the first quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock worth $346,000 after buying an additional 15 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Laboratory Corporation of America Holdings by 0.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 4,143 shares of the medical research company’s stock worth $594,000 after buying an additional 31 shares during the last quarter. Finally, Intrust Bank NA boosted its position in Laboratory Corporation of America Holdings by 1.1% in the first quarter. Intrust Bank NA now owns 4,065 shares of the medical research company’s stock worth $583,000 after buying an additional 43 shares during the last quarter. 91.64% of the stock is owned by institutional investors.

Shares of Laboratory Corporation of America Holdings (NYSE:LH) opened at 153.91 on Friday. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $164.22. The firm has a market cap of $15.67 billion, a price-to-earnings ratio of 21.56 and a beta of 0.94. The company’s 50-day moving average is $155.89 and its 200 day moving average is $145.06.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The business had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same period in the previous year, the business earned $2.36 EPS. The firm’s revenue was up 4.9% on a year-over-year basis. On average, equities research analysts expect that Laboratory Corporation of America Holdings will post $9.50 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/laboratory-corporation-of-america-holdings-lh-shares-bought-by-john-g-ullman-associates-inc-updated-updated.html.

LH has been the topic of a number of recent analyst reports. Craig Hallum restated a “buy” rating and issued a $179.00 target price (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Credit Suisse Group lowered shares of Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 target price on the stock. in a research note on Thursday, July 13th. They noted that the move was a valuation call. Barclays PLC restated an “overweight” rating and issued a $182.00 target price (up previously from $175.00) on shares of Laboratory Corporation of America Holdings in a research note on Monday, July 17th. BidaskClub upgraded shares of Laboratory Corporation of America Holdings from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 28th. Finally, Morgan Stanley upped their target price on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $159.75.

In other Laboratory Corporation of America Holdings news, SVP Lance Berberian sold 3,613 shares of the business’s stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $139.84, for a total value of $505,241.92. Following the completion of the transaction, the senior vice president now directly owns 5,789 shares of the company’s stock, valued at $809,533.76. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director R Sanders Williams sold 3,100 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $156.88, for a total transaction of $486,328.00. Following the sale, the director now directly owns 10,073 shares of the company’s stock, valued at $1,580,252.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,681 shares of company stock worth $2,743,227. 0.90% of the stock is owned by company insiders.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

What are top analysts saying about Laboratory Corporation of America Holdings? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Laboratory Corporation of America Holdings and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit